शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans

This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →

BSEMercury Laboratories Limited· Pharmaceuticals & BiotechnologyLowNeutral
Announced Thu, 29 Oct, 2026 · 10:20 IST

Board to approve September quarter and half-year results on 5 November

EBITDA margin compressionResults View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction

Awaiting price reaction for this filing.

AI summary

The board will meet on 5 November 2026 to approve unaudited results for the quarter and half-year ended 30 September 2026. The trading window has been closed since 1 October and will stay closed until 48 hours after results are announced.

Likely market impact

This is a routine scheduling notice with no earnings figures, so the results may affect the stock when announced.

By the numbersStandalone · Q2 FY27 vs Q2 FY26
Q2 FY27Q2 FY26Change
Revenue₹19.01 Cr₹19.01 Cr+0.0%
Operating profit₹0.54 Cr₹1.13 Cr−52.5%
Profit after tax₹0.67 Cr₹1.64 Cr−59.0%
EBITDA margin7.6%11.2%−3.6 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.